en
Scientific article
Open access
English

Identifying prodromal symptoms at high specificity for Parkinson's disease

Published inFrontiers in aging neuroscience, vol. 15, 1232387
Publication date2023
First online date2023-09-22
Abstract

Introduction: To test drugs with the potential to prevent the onset of Parkinson's disease (PD), it is key to identify individuals in the general population at high risk of developing PD. This is often difficult because most of the clinical markers are non-specific, common in PD but also common in older adults (e.g., sleep problems).

Objective: We aimed to identify the clinical markers at high specificity for developing PD by comparing individuals with PD or prodromal PD to healthy controls.

Methods: We investigated motor and non-motor symptoms (Movement Disorder Society Unified Parkinson's Disease Rating Scale Part 1 and 2 items) in 64 prodromal PD and 422 PD individuals calculating the odds ratios, adjusting for age and gender, for PD and prodromal PD versus 195 healthy controls. Symptoms at high specificity were defined as having an adjusted odds ratio ≥ 6.

Results: Constipation had an adjusted odds ratio, 6.14 [95% CI: 2.94-12.80] showing high specificity for prodromal PD, and speech difficulties had an adjusted odds ratio, 9.61 [95% CI: 7.88-48.81] showing high specificity for PD. The proportion of participants showing these specific markers was moderate (e.g., prevalence of constipation was 43.75% in prodromal PD, and speech difficulties was 33.89% in PD), suggesting these symptoms may make robust predictors of prodromal PD and PD, respectively.

Discussion: Clinical markers at high specificity for developing PD could be used as tools in the screening of general populations to identify individuals at higher risk of developing PD.

eng
Keywords
  • Parkinson’s disease
  • Observational study
  • Prevalence
  • Prodromal symptoms
  • Specificity
Affiliation Not a UNIGE publication
Citation (ISO format)
JACKSON, Holly et al. Identifying prodromal symptoms at high specificity for Parkinson’s disease. In: Frontiers in aging neuroscience, 2023, vol. 15, p. 1232387. doi: 10.3389/fnagi.2023.1232387
Main files (1)
Article (Published version)
Secondary files (1)
Identifiers
ISSN of the journal1663-4365
18views
5downloads

Technical informations

Creation10/24/2023 8:21:07 AM
First validation01/08/2024 10:43:42 AM
Update time01/08/2024 10:43:42 AM
Status update01/08/2024 10:43:42 AM
Last indexation02/01/2024 11:15:46 AM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack